{"title":"Metal-Based Anticancer Agents: In vitro DNA Binding, Cleavage and Cytotoxicity","authors":"Mala Nath, Nagamani Kompelli, Partha Roy, Snehasish Das","volume":92,"journal":"International Journal of Materials and Metallurgical Engineering","pagesStart":471,"pagesEnd":478,"ISSN":"1307-6892","URL":"https:\/\/publications.waset.org\/pdf\/9998954","abstract":"
Two new metal-based anticancer chemotherapeutic
\r\nagents, [(Ph2Sn)2(HGuO)2(phen)Cl2] 1 and [(Ph3Sn)(HGuO)(phen)]-
\r\nCl.CH3OH.H2O 2, were designed, prepared and characterized by
\r\nanalytical and spectral (IR, ESI-Mass, 1H, 13C and 119Sn NMR)
\r\ntechniques. The proposed geometry of Sn(IV) in 1 and 2 is distorted
\r\noctahedral and distorted trigonal-bipyramidal, respectively. Both 1
\r\nand 2 exhibit potential cytotoxicity in vitro against MCF-7, HepG-2
\r\nand DU-145 cell lines. The intrinsic binding constant (Kb) values of 1
\r\n(2.33 × 105 M-1) and 2 (2.46 × 105 M-1) evaluated from UV-Visible
\r\nabsorption studies suggest non-classical electrostatic mode of
\r\ninteraction via phosphate backbone of DNA double helix. The Stern-
\r\nVolmer quenching constant (Ksv) of 1 (9.74 × 105 M-1) and 2 (2.9 ×
\r\n106 M-1) determined by fluorescence studies suggests the groove
\r\nbinding and intercalation mode for 1 and 2, respectively. Effective
\r\ncleavage of pBR322 DNA is induced by 1.Their interaction with
\r\nDNA of cancer cells may account for potency.<\/p>\r\n","references":"[1] S. G. Ward, R. C. Taylor, \"Anti-tumor activity of the main-group\r\nelements: aluminum, gallium, indium, thallium, germanium, lead,\r\nantimony and bismuth,\u201d in Metal-Based Anti-Tumor Drugs, M. F.\r\nGielen, Ed. London: Freund Publishing House, 1988, pp. 1.\r\n[2] P. K\u00a8opf-Maier, H. K\u00a8opf, \" Non-platinum-group metal antitumor\r\nagents: history, current status, and perspectives,\u201d Chem. Rev., vol. 87,\r\n1987, pp. 1137\u20131152.\r\n[3] B. K. Keppler, C. Friesen, H. G. Moritz, H. Vongerichten, E. Vogel,\r\n\"Tumor inhibiting bis(\u03b2-diketonato) metal complexes. Budotitane, cisdiethoxybis(\r\n1-phenylbutane-1,3- dionato)titanium-(IV); The first\r\ntransition metal complex after platinum to qualify for clinical trials,\u201d\r\nStruct. Bond., vol. 78, 1991, pp. 97\u2013127.\r\n[4] S. Fruhauf, W. J. Zeller, \"In vitro evaluation of platinum, titanium and\r\nruthenium metal complexes in cisplatin-sensitive and -resistant rat\r\novarian tumors,\u201d Cancer Chemoth. Pharm., vol. 27, 1991, pp. 301\u2013307.\r\n[5] G. Sava, S. Zorzet, T. Giraldi, \"Antineoplastic activity and toxicity of an\r\norganometallic complex of ruthenium(II) in comparison with cis-PDD in\r\nmice bearing solid malignant neoplasms,\u201d Eur. J. Cancer Clin. Oncol.,\r\nvol. 20, 1984, pp. 841\u2013847.\r\n[6] C. Pettinari, F. Marchetti, \"Chemical and biotechnological developments\r\nin organotin cancer chemotherapy,\u201d in Tin Chemistry, Fundamentals,\r\nFrontiers, and Applications, A. G. Davies, M. Gielen, K. H. Pannell, and\r\nE. R. T. Tiekink, Ed. New York: JohnWiley & Sons, 2008, pp. 454\u2013468.\r\n[7] A. K. Saxena, F. Huber, \"Organotin compounds and cancer\r\nchemotherapy,\u201d Coord. Chem. Rev., vol. 95, 1989, pp. 109\u2013123.\r\n[8] M. Gielen, P. Lelieveld, D. de Vos, R. Willem, \"In vitro antitumor\r\nactivity of organotin compounds,\u201d in Metal-Based Antitumor Drugs, M.\r\nGielen Ed. London: Freund Publishing House, 1992.\r\n[9] M. J. Clarke, F. Zhu, D. R. Frasca, \"Non-platinum chemotherapeutic\r\nmetallopharmaceuticals,\u201d Chem. Rev., vol. 99, 1999, pp. 2511\u20132533.\r\n[10] M. Nath, S. Pokharia, R. Yadav, \"Organotin(IV) complexes of amino\r\nacids and peptides,\u201d Coord. Chem. Rev., vol. 215, 2001, pp. 99\u2013149.\r\n[11] Q. Li, P. Yang, H. Wang, G. Maolin, \"Diorganotin(IV) antitumor agent.\r\n(C2H5)2SnCl2 (phen)\/nucleotides aqueous and solid-state coordination\r\nchemistry and its DNA binding studies,\u201d J. Inorg. Biochem., vol. 64,\r\n1996, pp. 181\u2013195.\r\n[12] R. Huang, A. Wallqvist, D. G. Covell, \"Anticancer metal compounds in\r\nNCI\u2019s tumor-screening database: putative mode of action,\u201d Biochem.\r\nPharmacol., vol. 69, 2005, pp. 1009\u20131039.\r\n[13] F. Arjmand, G. C. Sharma, F. Sayeed, M. Muddassir, S. Tabassum, \"De\r\nnovo design of chiral organotin cancer drug candidates: validation of\r\nenantiopreferential binding to molecular target DNA and 5\u2019-GMP by\r\nUV\u2013visible, fluorescence, 1H and 31P NMR,\u201d J. Photochem. Photobiol.,\r\nvol. 105, 2011, pp. 167\u2013174.\r\n[14] C. F. J. Barnard, M. J. Cleare, P. C. Hydes, \"Second generation\r\nanticancer platinum compounds,\u201d Chem. in Brit., vol. 22, 1986, pp.\r\n1001\u20131004.\r\n[15] B. Desoize, \"Cancer and metals and metal compounds: part II\u2014cancer\r\ntreatment,\u201d Crit. Rev. Oncol. Hematol., vol. 42, 2002, pp. 213\u2013215.\r\n[16] B. Desoize, C. Madoulet, \"Particular aspects of platinum compounds\r\nused at present in cancer treatment,\u201d Crit. Rev. Oncol. Hematol., vol. 42,\r\n2002, pp. 317\u2013325.\r\n[17] P. Yang, M. Guo, \"Interactions of organometallic anticancer agents with\r\nnucleotides and DNA,\u201d Coord. Chem. Rev., vol. 185\u2013186, 1999, pp.\r\n189\u2013211.\r\n[18] L. Pellerito, L. Nagy, \"Organotin(IV)n+ complexes formed with\r\nbiologically active ligands: equilibrium and structural studies, and some\r\nbiological aspects,\u201d Coord. Chem. Rev., vol. 224, 2002, pp. 111\u2013150.\r\n[19] S. Tabassum, C. Pettinari, \"Chemical and biotechnological\r\ndevelopments in organotin cancer chemotherapy,\u201d J. Organomet. Chem.,\r\nvol. 691, 2006, pp. 1761\u20131766.\r\n[20] Zolt\u00b4an Szab\u00b4o, \"Multinuclear NMR studies of the interaction of metal\r\nions with adenine-nucleotides,\u201d Coord. Chem. Rev., vol. 252, 2008, pp.\r\n2362\u20132380.\r\n[21] A. Alama, B. Tasso, F. Novelli, F. Sparatore, \"Organometallic\r\ncompounds in oncology: implications of novel organotins as antitumor\r\nagents,\u201d Drug Discov. Today, vol. 14, 2009, pp.9-10.\r\n[22] A. M. Florea, D. B\u00fcsselberg, \"Anti-cancer drugs interfere with\r\nintracellular calcium signaling,\u201d NeuroToxicol., vol. 1006, 2009, pp. 1\u2013\r\n8.\r\n[23] S. K. Hadjikakou, N. Hadjiliadis, \"Antiproliferative and anti-tumor\r\nactivity of organotin compounds,\u201d Coord. Chem. Rev., vol. 253, 2009,\r\npp. 235\u2013249.\r\n[24] A. Y. Louie, T. J. Meade, \"Metal complexes as enzyme inhibitors,\u201d\r\nChem. Rev., vol. 99, 1999, pp. 2711\u20132734.\r\n[25] P. J. Barnard, S. J. Berners-Price, \"Target in the mitochondrial cell death\r\npathway with gold compounds,\u201d Coord. Chem. Rev., vol. 251, 2007, pp.\r\n1889\u20131902.\r\n[26] J. D. Robertson, S. Orrenius, \"Role of mitochondria in toxic cell death,\u201d\r\nToxicology, vol. 181\u2013182, 2002, pp. 491\u2013496.\r\n[27] A. J. Crowe, \"The chemotherapeutic properties of tin compounds\u201d,\r\nDrugs Future, vol. 12, 1987, pp. 255\u2013275.\r\n[28] M. Gielen, Tin-Based Antitumor Drugs, Springer Verlag, Berlin, 1990.\r\n[29] M. Gielen, E. R. T. Tiekink, Tin compounds and their therapeutic\r\npotential, Metallotherapeutic Drugs and Metal-Based Diagnostic\r\nAgents. The Use of Metals in Medicine, JohnWiley & Sons, New York,\r\n2005.\r\n[30] R. C. Poller, The chemistry of organotin compounds, Logos Press\r\nLimited, London, 1970.\r\n[31] A. G. Davies, Organotin chemistry, VCH, Weinheim, Germany, 2004.\r\n[32] M. Gielen, \"An overview of forty years organotin chemistry developed\r\nat the Free Universities of Brussels ULB and VUB,\u201d J. Braz. Chem.\r\nSoc., vol. 14, 2003, pp. 1.\r\n[33] M. Nath, S. Pokharia, G. Eng, X. Song, M. Gielen, M. Kemmer, M.\r\nBiesemans, R. Willem, D. de Vos, \"New organotin(IV) derivatives of\r\ndipeptides as models for metal-protein interactions: In vitro antitumor\r\nactivity,\u201d Appl. Organmet. Chem., vol. 17, 2003, pp. 305\u2013314.\r\n[34] M. Nath, M. Vats, P. Roy, \"Di- and triorganotin(IV) complexes of\r\nbiologically important orotic acid: synthesis, spectroscopic studies, in\r\nvitro anti-cancer, DNA fragmentation, enzymes assays, and in vivo antiinflammatory\r\nactivities,\u201d Eur. J. Med. Chem., vol. 59, 2013, pp.310\u2013\r\n321.\r\n[35] S. R. Collinson, D. E. Fenton, \"Metal complexes of bibracchial Schiff\r\nbase macrocycles,\u201d Coord. Chem. Rev., vol. 148, 1996, pp. 19.\r\n[36] M. Nath, S. Pokharia, G. Eng, X. Song, A. Kumar, \"Comparative study\r\nof structure-activity relationship of di- and triorganotin( IV) derivatives\r\nof amino acid and peptides,\u201d J. Organomet. Chem., vol. 669, 2003, pp.\r\n109\u2013123.\r\n[37] M. Nath, S. Pokharia, G. Eng, X. Song, A. Kumar, \"Diorganotin(IV)\r\nderivatives of dipeptides containing at least one essential amino acid\r\nresidue: synthesis, characteristic spectral data, cardiovascular, and antiinflammatory\r\nactivities,\u201d Synth. React. Inorg. Metal-Org. Chem., vol.\r\n34, 2004, pp. 1689\u20131708.\r\n[38] M. Nath, R. Jairath, G. Eng, X. Song, A. Kumar, \"Interaction of\r\ntriorganotin(IV) cations with pyrimidine bases\/nucleoside: synthesis,\r\nspectral characterization and biological studies of a novel\r\ntriphenyltin(IV) derivative of thymidine,\u201d Inorg. Chem. Commun., vol.\r\n7, 2004, pp. 1161\u20131163.\r\n[39] M. Nath, S. Pokharia, G. Eng, X. Song, A. Kumar, M.Gielen, R.\r\nWillem, M. Biesemans, \"New trimethyltin(IV) derivatives of dipeptides:\r\nsynthesis, characteristic spectral studies and biological activity,\u201d Appl.\r\nOrganomet. Chem., vol. 18, 2004, pp. 460\u2013470.\r\n[40] M. Nath, S. Pokharia, G. Eng, X. Song, A. Kumar, \"New\r\ntriorganotin(IV) derivatives of dipeptides as anti-inflammatoryantimicrobial\r\nagents,\u201d Eur. J. Med. Chem., vol. 40, 2005, pp. 289\u2013298.\r\n[41] M. Nath, S. Pokharia, G. Eng, X. Song, A. Kumar, \"New triorganotin\r\n(IV) derivatives of dipeptides as models for metal-protein interactions:\r\nsynthesis, structural characterization and biological studies,\u201d\r\nSpectrochim. Acta\u2014Part A, vol. 63, 2006, pp. 66\u201375.\r\n[42] M. Nath, H. Singh, P. Kumar, A. Kumar, X. Song, G. Eng,\r\n\"Organotin(IV) tryptophanylglycinates: potential nonsteroidal anti\r\ninflammatory agents; crystal structure of dibutyltin(IV)\r\ntryptophanylglycinate,\u201d Appl. Organomet. Chem., vol. 23, 2009, pp.\r\n347\u2013358.\r\n[43] M.Nath, H. Singh, G. Eng, X. Song, A. Kumar, \"Syntheses,\r\ncharacterization and biological activity of diorganotin(IV) derivatives of\r\n2-amino-6-hydroxypurine (guanine),\u201d Inorg. Chem. Commun., vol. 12,\r\n2009, pp. 1049\u20131052.\r\n[44] M. Nath, H. Singh, G. Eng, X. Song, \"Interaction of organotin(IV)\r\nmoieties with nucleic acid constituent: synthesis, structural\r\ncharacterization and anti-inflammatory activity of tri-n-propyltin(IV)\r\nand diorganotin(IV) derivatives of guanosine,\u201d Inorg. Chem. Commun.,\r\nvol. 14, 2011, pp. 1381\u20131385.\r\n[45] M. Nath, H. Singh, G. Eng, X. Song, \"Interaction of 5\u2019-guanosine\r\nmonophosphate with organotin(IV) moieties: synthesis, structural\r\ncharacterization, and anti-inflammatory activity,\u201d ISRN Org. Chem.,\r\n2012, pp. 1\u20139.\r\n[46] M. I. Khan, M. K. Baloch, M. Ashfaq, G. Stoter, \"In vivo toxicological\r\neffects and spectral studies of new triorganotin(IV)\u2013N\u2013\r\nmaleoyltranexanates,\u201d J. Organomet. Chem., vol. 691, 2006, pp. 2554.\r\n[47] A. Atkinson, M. D. Rodriguez, T. E. Shewmaker, J. A. Walmsley,\r\n\"Synthesis and characterization of compounds of di- and tributyltin\r\nchloride with adenine and guanine mononucleotides,\u201d Inorg. Chim.\r\nActa, vol. 285, 1999, pp. 60\u201369.\r\n[48] H. Jankovics, L. Nagy, N. Buz\u00b4as, L. Pellerito, R. Barbieri,\r\n\"Coordination properties of adenosine-5\u2019-monophosphate and related\r\nligands towards Me2Sn(IV)2+ in aqueous solution,\u201d J. Inorg. Biochem.,\r\nvol. 92, 2002, pp. 55.\r\n[49] F. Gharib, E. Farzad, M. M. Amini, \"Interaction of dimethyltin(IV)\r\ndichloride with 5\u2019-AMP and 5\u2019-GMP,\u201d Can. J. Chem., vol. 84, 2006, pp.\r\n1534.\r\n[50] S. Roy, K. D. Hagen, P. U. Maheswari, M. Lutz, A. L. Spek, J.\r\nReedijk, G. P. van Wezel, \"Phenanthroline derivatives with improved\r\nselectivity as DNA-targeting anticancer or antimicrobial drugs,\u201d Chem.\r\nMed. Chem., vol. 3, 2008, pp. 1427\u20131434.\r\n[51] W. D. Honnick, M. C. Hughes, C. D. Schaeffer, Jr., J. J. Zuckerman,\r\n\"Tin\u2013 119m m\u00f6ssbauer, infrared, nuclear magnetic resonance,\r\nequilibrium, and thermodynamic measurements on complexes of\r\ndimethyltin dichloride with substituted 1,l0-phenanthrolines and 2,2'-\r\nbipyridines,\u201d Inorg. Chem., vol. 15, 1976, pp. 1391\u20131396.\r\n[52] M. E. Reicmann, S. A. Rice, C. A. Thomas, P. Doty, \"A further\r\nexamination of the molecular weight and size of desoxypentose nucleic\r\nacid,\u201d J. Am. Chem. Soc., vol. 76, 1954, pp. 3047\u20133053.\r\n[53] L. F. Tan, H. Chao, K. C. Zhen, J. J. Fei, F. Wang, Y. F. Zhou, N. J.\r\nLiang, \"Co(III) complexes of Me-salpn and Me-salbn and the ring size\r\neffect on the coordination modes and electrochemical properties: the\r\ncrystal structures of trans-[CoIII(Me-salpn)(py)2]PF6 and cis-\u03b1-[CoIII(Me-salbn)(4-Mepy)2]BPh4 4-Mepy,\u201d Polyhedron, vol. 26, 2007,\r\npp. 5448\u20135457.\r\n[54] L. J. Childs, J. Malina, B. E. Rolfsnes, M. Pascu, M. J. Prieto, M. J.\r\nBroome, P. M. Rodger, E. Sletten, V. Moreno, A. Rodger, M. J. Hannon,\r\n\"A DNA-binding copper(I) metallosupramolecular cylinder that acts as\r\nan artificial nuclease,\u201d Chem..Eur. J., vol. 12, 2006, pp. 4919\u20134927.\r\n[55] S. Yellappa, J. Seetharamappa, L. M. Rogers, R. Chitta, R. P. Singhal, F.\r\nD\u2019Souza, \"Binding, electrochemical activation, and cleavage of DNA by\r\nCobalt(II) Tetrakis-N-methylpyridyl Porphyrin and its \u03b2-Pyrrole\r\nbrominated derivative,\u201d Bioconjugate Chem., vol. 17, 2006, pp. 1418\u2013\r\n1425.\r\n[56] S. Satyanarayana, J. C. Dabrowiak, J. B. Chaires, \"Neither DELTA- nor\r\nLAMBDA -tris(phenanthroline)ruthenium(II) binds to DNA by classical\r\nintercalation,\u201d Biochemistry, vol. 31, 1992, pp. 9319\u20139324.\r\n[57] D. -L. Ma, C. -M. Che, \"A bifunctional platinum(II) complex capable of\r\nintercalation and hydrogen-bonding interactions with DNA: Binding\r\nstudies and cytotoxicity,\u201d Chem. Eur. J., vol. 9, 2003, pp. 6133\u20136144.\r\n[58] D. -L. Ma, C. -M. Che, F. -M. Siu, M. Yang, K. -Y. Wong, \"DNA\r\nbinding and cytotoxicity of ruthenium(II) and rhenium(I) complexes of\r\n2-Amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine,\u201d Inorg. Chem.,\r\nvol. 46, 2007, pp. 740\u2013749.\r\n[59] S. Wang, R. Cosstick, J. F. Gardner, R. I. Gumport, \"The specific\r\nbinding of Escherichia coli integration host factor involves both major\r\nand minor grooves of DNA,\u201d Biochemistry, vol. 34, 1995, pp.13082\u2013\r\n13090.\r\n[60] S. Tabassum, R. A. Khan, F. Arjmand, M. Aziz, A. S. Juvekar, S. M.\r\nZingde, \"Carbohydrate-conjugate heterobimetallic complexes: synthesis,\r\nDNAbinding studies, artificial nuclease activity and in vitro\r\ncytotoxicity,\u201d Carbohydr. Res., vol. 346, 2011, pp. 2886\u20132895.\r\n[61] K. Aoki, \"The Anti-tumor activity of tin compounds,\u201d in Metal-Based\r\nAnti-Tumor Drugs, M. F. Gielen, Ed. London: Freund Publishing House,\r\n1988, pp. 127.","publisher":"World Academy of Science, Engineering and Technology","index":"Open Science Index 92, 2014"}